Prediction of native coronary artery disease progression following PTCA or CABG in the Emory Angioplasty Versus Surgery Trial

Medical Science Monitor

Volumn 9, Issue 2, 2003, Pages

  Zhao, Xue Qiao ^a,d   Kosinski, Andrzej S ^b   Barnhart, Huiman X ^b   Superko, H Robert ^c   King III, Spencer B ^b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Berkeley HeartLab Inc   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Coronarydisease; Lesion; Lipids; Revascularization; Riskfactors

Indexed keywords

LOW DENSITY LIPOPROTEIN;

ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; COMPARATIVE STUDY; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; CORRELATION ANALYSIS; DISEASE COURSE; ELECTROCARDIOGRAM; FOLLOW UP; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; PREDICTION; Q WAVE; RISK ASSESSMENT; ST SEGMENT DEPRESSION; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

ANGIOGRAPHY; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY ARTERIOSCLEROSIS; CORONARY ARTERY BYPASS; DISEASE PROGRESSION; HUMANS; LIPOPROTEINS, LDL; MYOCARDIAL ISCHEMIA; PARTICLE SIZE; RISK FACTORS;

EID: 0037297085     PISSN: 12341010     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Gruentzig AR: Transluminal dilation of coronary artery stenosis (letter). Lancet, 1978; 1: 263
2. Favaloro RG: Saphenous vein graft in the surgical treatment of coronary artery disease: operative technique. J Thorac Cardiovasc Surg, 1969; 58: 178-185
3. Heart Disease and Stroke Statistics - 2003 Update. Dallas Tex: American Heart Association, 2002
4. Pearson T, Rapaport E, Criqui M et al: Optimal risk factor management in the patient after coronary revascularization: a statement for healthcare professionals from an American Heart Association Writing Group. Circulation, 1994; 90: 3125-3133
5. Hasdai D, Bell MR, Grill DE et al: Outcome 110 years after successful percutaneous transluminal coronary angioplasty. Am j Cardiol, 1997; 79: 1005-1011
6. Fitzgibbon GM, Katka HP, Leach AJ et al: Coronary bypass graft fate and patient outcome: angiographic follow-up of 5,065 grafts related to survival and reoperation in 1,388 patients during 25 years. Am J Cardiol, 1996; 28: 616-626
7. King SB III, Lembo NJ, Hall EC, EAST Investigators: The Emory Angioplasty vs. Surgery Trial (EAST): analysis of baseline characteristics. Am J Cardiol, 1995; 75: 42-59
8. King SB III, Lembo NJ, Weintraub WS, for the Emory Angioplasty Versus Surgery Trial (EAST) et al: A Randomized Trial Comparing Coronary Angioplasty with Coronary Bypass Surgery. N Engl J Med, 1994; 331: 1044-1050
9. Zhao XQ, Brown BG, Stewart DK et al: Effectiveness of revascularization in the Emory Angioplasty vs. Surgery Trial (EAST): A randomized comparison of coronary angioplasty with bypass surgery. Circulation, 1996; 93: 1954-1962
10. CASS: Principal Investigators and their Associates. Coronary artery surgery study (CASS). A randomized trial of coronary artery bypass surgery. Quality of life in patients randomly assigned to treatment groups. Circulation, 1983; 68: 951-960
11. Brown BG, Bolson EL, Frimer M, Dodge HT: Quantitative coronary arteriography: estimation of dimensions, hemodynamic resistance, and atheroma mass of coronary artery lesions using the arteriogram and digital computation. Circulation, 1977; 55: 329-337
12. Scoblionko DP, Brown BG, Mitten S et al: A New Digital Electronic Caliper for Measurement of Coronary Arterial Stenosis: Comparison with Visual Estimates and Computer-Assisted Measurements. J Am Coll Cardiol, 1984; 53: 689-693
13. Dodge JT Jr, Brown BG, Bolson EL, Dodge HT: Intrathoracic spatial location of specified coronary segments on the normal human heart. Application in quantitative arteriography, assessment of myocardial mass and regional contraction, and anatomic display. Circulation, 1988; 78: 1176-1180
14. Krauss RM, Blanche PJ: Detection and quantitation of LDL subfractions. Current Opinion in Lipidology, 1992; 3: 377-383
15. Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem, 1972; 18: 499-509
16. Fisher LD, Belle GV: Biostatistics: a methodology for the health sciences. New York, John Wiley, 1993
17. Hosmer DW, Lemeshow S: Applied logistic regression. New York: Joyn Wiley, 1989
18. Brown BG, Albers JJ, Fisher LD et al: Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med, 1990; 323(19): 1289-1298
19. Zhao XQ, Brown BG, Hillger LA et al: Effects of intensive lipid-lowering on the coronary arteries of asymptomatic subjects with elevated apolipoprotein B. Circulation, 1993; 88: 2744-2753
20. Buchwald H, Matts JP, Fitch LL et al: Change in sequential coronary arteriograms and subsequent coronary events. JAMA, 1992; 268: 1429-1433
21. Waters D, Craven TE, Lesperance J: Prognostic significance of progression of coronary atherosclerosis. Circulation, 1993; 87: 1067-1076
22. Gardner CD, Fortmann SP, Krauss RM: Small low density lipoprotein particles are associated with the incidence of coronary artery disease in men and women. JAMA, 1996; 276: 875-881
23. Stampfer MJ, Krauss RM, Blanche PJ et al: A Prospective Study of Triglyceride Level, Low Density Lipoprotein Particle Diameter, and Risk of Myocardial infarction. JAMA, 1996; 276: 882-888
24. Lamarche B, Tchernof A, Moorjani S et al: Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Quebec cardiovascular study. Circulation, 1997; 95: 69-75
25. Austin MA, Kamigaki A, Hokanson JE: Los-density lipoprotein particle size is a risk factor for coronary heart disease independent of triglyceride and HDL cholesterol: a meta-analysis of three prospective studies in men. Circulation, 1999; 99: 1124 (abstr)
26. Miller BD, Alderman EL, Haskell WL et al: Predominance of dense low-density lipoprotein particles predicts angiographic benefit or therapy in the Stanford Coronary Risk Intervention project. Circulation, 1996; 94: 2146-2153
27. Superko HR: Did Grandma Give you heart disease? The new battle against coronary artery disease. Am J Card, 1998; 82: 34-46
28. Tselepis AD, Dentan C, karabina SAP et al: PAF-degrading acetylhydrolase is preferentially associated with dense LDL and VHDL-1 in human plasma. Arterioscler Thromb Vasc Biol, 1995; 15: 1764-1773
29. Nordestgaard BG, Wootton R, Lewis B: Selective retention of VLDL, IDL, and LDL in the arterial intima of genetically hyperlipidemic rabbits in vivo. Molecular size as a determinant of fractional loss from the intima-inner media. Arterioscler Thromb Vasc Biol, 1995; 15: 534-42
30. Nishina PM, Johnson JP, Naggert JK, Krauss RM: Linkage of atherogenic lipoprotein phenotype to the low-density lipoprotein receptor locus on the short arm of chromosome 19. Proc Natl Acad Sci USA, 1992; 89: 708-712
31. Superko HR: Lipid Altering Drugs LDL/HDL subclass Distribution. Match the Treatment to the Disorder. ACC Current Journal Review, 2000; 9(3): 18-24